Second-generation CML drugs show promise as frontline therapy

Two drugs approved as fallback therapy for chronic myelogenous leukemia appear to outperform historical benchmarks of the frontline medication when used as a first treatment in separate clinical trials, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 50th Annual Meeting of the American Hematological Society.